Scientific Publications

ACE publishes key technical evaluations and processes in scientific journals and often presents scientific content at regional and international symposiums and conferences.

Journal Publications

Title

Publication

Date of publication

Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 24 - Issue 2 December 2023 
What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward International Journal of Health Policy and Management, Vol. 12 - Issue 1  March 2023 
Horizon Scanning To Nominate Subsidy Evaluation Topics For Medical Technologies: Early Experience From Singapore International Journal of Technology Assessment in Health Care, Vol. 38 - Special Issue S1
January 2023 
Developing a New Region-Specific Preference-Based Measure in East and Southeast Asia Value in Health Regional Issues 37   November 2022
Real-world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes  JGH Open, Vol. 7 - Issue 1 November 2022 
Cost-effectiveness of transcatheter aortic valve implantation in patients with severe symptomatic aortic stenosis of intermediate surgical risk in Singapore  BMC Health Services Research, Vol. 22 August 2022 
Measuring Real-World Impact of Subsidy Decision on Sleep Tests Utilisation for the Diagnosis of Obstructive Sleep Apnoea  Value in Health, Vol. 25 - Issue 7  July 2022
Real-World Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Patients with Non-Valvular Atrial Fibrillation (NVAF): A Retrospective Cohort Study in Singapore Value in Health, Vol. 25 - Issue 7 July 2022 
Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study Journal of Diabetes & Metabolic Disorders, Vol. 21 March 2022 
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 22 - Issue 2 December 2021
Cost-effectiveness analysis of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore BMC Health Services Research, Vol. 21 - Article 909 September 2021 
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
 Vaccine, Vol. 39 - Issue 16 April 2021
A review of implementation frameworks to operationalize health technology assessment recommendations for medical technologies in the Singapore setting
International Journal of Technology Assessment in Health Care, Vol. 37 - Issue 1 April 2021
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 21 - Issue 3 March 2021
A landscape analysis of health technology assessment capacity in the Association of South‑East Asian Nations region Health Research and Policy Systems, Vol. 19   February 2021

Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore

Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 21 - Issue 3 February 2021

Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore

Journal of Asthma, Vol. 59 - Issue 1

October 2020

Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore

 Cancer Reports, Vol. 4 - Issue 1

October 2020

Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward International Journal of Technology Assessment in Health Care, Vol. 36 - Issue 5   September 2020

Cost-effectiveness analysis of osimertinib for first line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

Journal of Medical Economics, Vol 23 - Issue 11

September 2020

Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective

Journal of Medical Economics, Vol 23 - Issue 11

August 2020

Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer

Journal of Medical Economics, Vol. 23 - Issue 9

June 2020

Cost-effectiveness analysis of atezolizumab in advanced triple negative breast cancer

BMC Health Services Research, 20 - Article 581

June 2020

Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore

Journal of Medical Economics, Vol. 23 - Issue 8

May 2020

Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore

International Journal of Technology Assessment in Health Care, Vol. 36 - Issue 4

May 2020

Landscape analysis of health technology assessment (HTA): systems and practices in Asia International Journal of Technology Assessment in Health Care, Vol. 35 - Issue 6   October 2019

Cost effectiveness analysis of bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears in Singapore

PLOS One

August 2019

Health technology assessment and its use in drug policies: Singapore 

 Value in Health, Vol. 18

May 2019

Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore

International Journal of Technology Assessment in Health Care, Vol. 35 - Issue 2

March 2019

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis

International Journal of Chronic Obstructive Pulmonary Disease, Vol. 18

October 2018

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

 BMC Cancer, Vol. 18

March 2018

Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction

Journal of Medical Economics, Vol. 21 - Issue 2

October 2017


Conference Posters


Title

Conference

 Date

Characteristics of Patients with Symptomatic Severe Aortic Stenosis Who Underwent Transcatheter Aortic Valve Implantation (TAVI): A Real-World Study in Singapore
 ISPOR Europe 2023  November 2023   
Cost-Effectiveness Analysis of Molnupiravir Against Standard Care for Treating Mild to Moderate COVID-19 Infection in Singapore  ISPOR Europe 2023  November 2023   
Cost-Effectiveness of Inclisiran as Add-on Therapy to Standard-of-Care for the Secondary Prevention of Cardiovascular Events in Patients with Elevated LDL Cholesterol  ISPOR Europe 2023  November 2023   
Real-world utilisation and outcomes of transcatheter mitral valve leaflet repair (TMVLR) in Asian patients with mitral regurgitation: A Singapore experience  ISPOR Europe 2023  November 2023   
The association of ESMO-Magnitude of Clinical Benefit Scale scores and subsidy decisions of targeted therapies for solid tumours in Singapore ISPOR Europe 2023 
November 2023  
Patient Involvement in Drug Evaluations to Inform Funding Decisions: A Singapore Case Study HTAi 2023 June 2023  
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Chemotherapy for Previously Treated HER2-Positive Gastric Cancer in Singapore HTAi 2023 June 2023  
Increasing Emergence of Novel Digital Health Technologies Identified Through Horizon Scanning HTAi 2023 June 2023  
Early Health Technology Assessment (HTA) of Medical Technologies to Inform Subsidy Decision-making in Singapore HTAi 2023 June 2023  
Are We Ready for It? Developing Criteria to Include Artificial Intelligence Medical Devices (AI-MDs) For Health Technology Assessment (HTA) HTAi 2023 June 2023 
Measuring the impact of subsidy decision on bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in Singapore HTAsialink 2021 October 2021 
Real-world data for measuring the impact of health technology assessment of drugs in Singapore HTAsialink 2021 October 2021 
Effect of drug subsidy policy on empagliflozin utilisation in Singapore: An interrupted time series analysis 13th Asian Conference on Pharmacoepidemiology in Seoul, Korea (Virtual) October 2021 
Changes in prescribing practice of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in Singapore 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) (Virtual) September 2020
Funding of treatments for rare diseases in Singapore 17th HTA International Annual Meeting, Beijing, China (Virtual) June 2020
Meta-Analysis of omalizumab and ciclosporin for chronic spontaneous urticaria 16th HTA International Annual Meeting in Cologne, Germany June 2019
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) in chronic obstructive pulmonary disease: A systematic review and network meta-analysis 8th ISPOR Asia Pacific in Tokyo, Japan  September 2018
Fluorodeoxyglucose positron emission tomography with computerised tomography for oncological indications: a pragmatic approach to guide subsidy decisions 8th ISPOR Asia Pacific in Tokyo, Japan  September 2018
Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore 8th ISPOR Asia Pacific in Tokyo, Japan  September 2018
A pilot trial of value-based pricing for medical devices 15th HTA International Annual Meeting in Vancouver, Canada June 2018
Selection of non-drug medical technologies for evaluation in Singapore 15th HTA International Annual Meeting in Vancouver, Canada June 2018
Evolution of national drug evaluation processes in Singapore 15th HTA International Annual Meeting in Vancouver, Canada June 2018